Beta-2 Microglobulin in Patients on Peritoneal Dialysis and Hemodialysis

Serum β2 microglobulin ( β2μ) levels were determined in 62 patients on chronic dialysis, divided according to the type of dialysis-cuprophane hemodialysis, chronic ambulatory peritoneal dialysis (CAPD), or CAPD staned after 76 ± 47 months on cuprophane hemodialysis-and to residual urine output greater than 400 mLlday or less than 10 mL/day. In addition, for patients on CAPD, peritoneal excretion, peritoneal clearance, and urinary excretion of the protein were determined. In anuric patients serum β2μ levels were significantly higher in HD than in CAPD. In patients with residual urine output, serum concentrations of the microprotein were similar in HD and in CAPD. Significant differences were observed in β2μ serum levels and peritoneal clearances in patients switched to CAPD from hemodialysis as compared to those staning with CAPD. Peritoneal clearances of the microprotein was slightly and non-significantly greater in patients with urine output than in anuric patients.

Download Full-text

Serum Levels and Urinary Excretion of Beta-2-Microglobulin in Patients with Urinary Bladder Carcinoma

European Urology ◽

10.1159/000472942 ◽

1988 ◽

Vol 14 (3) ◽

pp. 218-221 ◽

Cited By ~ 1

Author(s):

Wilhelm Engström

Keyword(s):

Urinary Bladder ◽

Urinary Excretion ◽

Bladder Carcinoma ◽

Serum Levels ◽

Urinary Bladder Carcinoma ◽

Beta 2 ◽

Beta 2 Microglobulin

Download Full-text

Beta-2 Microglobulin in Peritoneal Dialysis Patients: Serum Levels and Peritoneal Clearances

Peritoneal Dialysis International ◽

10.1177/089686088800800110 ◽

1988 ◽

Vol 8 (1) ◽

pp. 43-47 ◽

Cited By ~ 14

Author(s):

Carol R. DiRaimondo ◽

Patricia McCarley ◽

William J. Stone

Keyword(s):

Peritoneal Dialysis ◽

Serum Levels ◽

Hemodialysis Patients ◽

Chronic Hemodialysis ◽

Bone Lesions ◽

Dialysis Patients ◽

Urea Nitrogen ◽

Pathologic Fractures ◽

Beta 2 ◽

Beta 2 Microglobulin

Beta-2 microglobulin (B2M) is amyloidogenic in long-term hemodialysis patients, with amyloid deposition manifesting as lytic bone lesions, carpal tunnel syndrome, destructive arthropathies, tenosynovitis, and pathologic fractures. To study the behavior of this protein in the peritoneal dialysis population, serum levels of B2M from 14 chronic peritoneal dialysis (CPD) patients (4IPD, 10 CAPD) were compared to those of 15 chronic hemodialysis patients, and peritoneal clearances were measured in 9 CAPD patients. Standard cuprophan dialyzers were used for hemodialysis. Serum B2M levels were significantly lower in the peritoneal dialysis group (mean ± SD 73.2 ± 20.9 mg/L) than in the hemodialysis group (100.3 ± 24.7 mg/L, p < .004). When CAPD patients alone were compared to the hemodialysis patients, lower serum B2M levels were again apparent, with mean 68.7 ± 16.4 mg/L (p ≤ .002). Mean serum B2M in IPD patients (84.6 ± 28.9 mg/L) did not differ statistically from either the CAPD or the hemodialysis group. Peritoneal clearance of B2M, urea nitrogen, and creatinine over a 6 h exchange were obtained in 9 CAPD patients without peritonitis. Mean clearance (±SD) of B2M was 0.9 ± 0.4 ml/min/1.73 m2, urea nitrogen 5.3 ± 0.3 ml/min/1.73 m2, and creatinine 4.2 ± 0.8 ml/min/1.73 m2. Mean loss of B2M via the peritoneal cavity was 19.9 ± 6.6 mg/2 L-exchange/1.73 m2 (range 7.7 to 26.2 mg/2 L-exchange/1.73 m2). Decreased serum B2M in peritoneal dialysis patients is consistent with increased clearance by the peritoneal membrane versus standard cellulosic hemodialysis membranes. Whether use of CPD rather than hemodialysis can prevent or even treat dialysis-associated amyloidosis (AB2M) remains speculative.

Download Full-text

Urinary Excretion of Beta-2-Microglobulin and Albumin During Antibiotic Therapy in Urinary Tract Infections

Urinary Proteins - Contributions to Nephrology ◽

10.1159/000396103 ◽

2015 ◽

pp. 42-49 ◽

Cited By ~ 3

Author(s):

F. P. Schena ◽

R. De Cesaris ◽

A. Tedesco ◽

E. La Raia ◽

L. Bonomo

Keyword(s):

Urinary Tract ◽

Antibiotic Therapy ◽

Urinary Excretion ◽

Urinary Tract Infections ◽

Beta 2 ◽

Beta 2 Microglobulin ◽

Tract Infections

Download Full-text

Effects of Probenecid on Renal Function in Surgical Patients Anesthetized with Low-flow Sevoflurane

Anesthesiology ◽

10.1097/00000542-200101000-00009 ◽

2001 ◽

Vol 94 (1) ◽

pp. 21-31 ◽

Cited By ~ 19

Author(s):

Hideyuki Higuchi ◽

Hiroki Wada ◽

Yumi Usui ◽

Kohichiro Goto ◽

Masuyuki Kanno ◽

...

Keyword(s):

Urinary Excretion ◽

Biochemical Markers ◽

High Flow ◽

Surgical Patients ◽

Low Flow ◽

Sevoflurane Anesthesia ◽

Compound A ◽

Significant Difference ◽

Beta 2 ◽

Beta 2 Microglobulin

Background Dehydrofluorination of sevoflurane by carbon dioxide absorbents in anesthesia machines produces compound A, which is nephrotoxic in rats. Several clinical studies indicate that prolonged low-flow sevoflurane anesthesia is associated with an increased urinary excretion of biochemical markers, such as protein. Probenecid, a competitive inhibitor of organic anion transport, diminishes compound A nephrotoxicity in rats. The purpose of the present study was to examine the effects of low- and high-flow sevoflurane anesthesia on urinary excretion of biochemical markers in humans and to examine the effects of probenecid on urinary excretion of these markers. Methods Elective surgical patients (n = 64) were assigned to four groups (n = 16 each): low-flow sevoflurane plus probenecid (LSP), low-flow sevoflurane (LS), high-flow sevoflurane plus probenecid (HSP), and high-flow sevoflurane (HS). Probenecid (2.0 g) was administered orally 2 h before the induction of anesthesia in both the LSP and HSP groups. Nothing was administered orally 2 h before the induction of anesthesia in either the LS or HS groups. All patients underwent prolonged low-flow (1 l/min) or high-flow (6 l/min) sevoflurane anesthesia. Urinary excretion of protein, albumin, beta(2)-microglobulin, glucose, and N-acetyl-beta-d-glucosaminidase was measured for up to 7 days postoperatively. Results Sevoflurane doses were similar in all four groups. There were no differences in blood urea nitrogen, creatinine, or creatinine clearance among the four groups after anesthesia. Average values for urinary excretion of protein, beta(2)-microglobulin, and N-acetyl-beta-d-glucosaminidase in the LS group were significantly higher than those in the other groups (LSP, HSP, HS; P < 0.05). There was no significant difference between the LS and LSP groups in average values for urinary excretion of albumin and glucose, although there were significant differences between the LS and both high-flow sevoflurane groups (HSP, HS). Conclusions Low-flow sevoflurane, which produces a sevenfold higher compound A exposure than high-flow sevoflurane, resulted in significant increases of several biochemical markers in half of the patients. Probenecid appears to provide protection against these renal effects.

Download Full-text

Prognostic role of serum beta 2-microglobulin in Hodgkin's disease.

Journal of Clinical Oncology ◽

10.1200/jco.1993.11.6.1108 ◽

1993 ◽

Vol 11 (6) ◽

pp. 1108-1111 ◽

Cited By ~ 33

Author(s):

M A Dimopoulos ◽

F Cabanillas ◽

J J Lee ◽

F Swan ◽

L Fuller ◽

...

Keyword(s):

Hodgkin's Disease ◽

Hodgkin’S Disease ◽

Elevated Serum ◽

Serum Levels ◽

Tumor Stage ◽

Stage Disease ◽

Lower Response Rate ◽

Beta 2 ◽

Beta 2 Microglobulin

PURPOSE To evaluate the role of serum beta 2-microglobulin (beta 2M) in the prognosis of patients with Hodgkin's disease. PATIENTS AND METHODS One hundred sixty previously untreated patients with Hodgkin's disease had serum beta 2M levels determined before initiation of treatment. Serum beta 2M was tested for its correlation with known prognostic factors for patients with Hodgkin's disease. These variables, including beta 2M, were correlated with complete remission (CR) rate and time to treatment failure (TTF). Univariate and multivariate analyses were performed. RESULTS Serum beta 2M levels greater than 2.5 mg/L were found in 29% of patients. Such elevation was more common in patients with more advanced-stage disease. Elevated serum beta 2M was an independent and powerful factor in the prediction of lower response rate and shorter TTF. Its impact appeared to be more significant in patients with advanced disease. CONCLUSION Serum beta 2M appears to correlate with tumor stage in patients with Hodgkin's disease and elevated serum levels of this polypeptide predict a less favorable prognosis.

Download Full-text